DE602004031881D1 - Verfahren und materialien zur beurteilung von prostatakrebstherapien - Google Patents

Verfahren und materialien zur beurteilung von prostatakrebstherapien

Info

Publication number
DE602004031881D1
DE602004031881D1 DE602004031881T DE602004031881T DE602004031881D1 DE 602004031881 D1 DE602004031881 D1 DE 602004031881D1 DE 602004031881 T DE602004031881 T DE 602004031881T DE 602004031881 T DE602004031881 T DE 602004031881T DE 602004031881 D1 DE602004031881 D1 DE 602004031881D1
Authority
DE
Germany
Prior art keywords
androgens
materials
prostate acid
acid therapies
assessing prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004031881T
Other languages
English (en)
Inventor
Charles L Sawyers
Charlie D Chen
Derek Welsbie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE602004031881D1 publication Critical patent/DE602004031881D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602004031881T 2003-12-19 2004-12-16 Verfahren und materialien zur beurteilung von prostatakrebstherapien Active DE602004031881D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53109103P 2003-12-19 2003-12-19
PCT/US2004/042221 WO2005060661A2 (en) 2003-12-19 2004-12-16 Methods and materials for assessing prostate cancer therapies

Publications (1)

Publication Number Publication Date
DE602004031881D1 true DE602004031881D1 (de) 2011-04-28

Family

ID=34710203

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004031881T Active DE602004031881D1 (de) 2003-12-19 2004-12-16 Verfahren und materialien zur beurteilung von prostatakrebstherapien

Country Status (9)

Country Link
US (1) US8034548B2 (de)
EP (2) EP2299266A1 (de)
JP (1) JP2007514442A (de)
AT (1) ATE502298T1 (de)
AU (1) AU2004305075A1 (de)
CA (1) CA2550447A1 (de)
DE (1) DE602004031881D1 (de)
NZ (1) NZ548209A (de)
WO (1) WO2005060661A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN105902559A (zh) 2005-08-01 2016-08-31 俄亥俄州立大学研究基金会 用于乳腺癌的诊断、预后和治疗的基于MicroRNA的方法和组合物
CN101296702B (zh) 2005-09-12 2012-11-28 俄亥俄州立大学研究基金会 用于诊断或治疗bcl2相关癌症的组合物和方法
EP2586455B1 (de) 2006-01-05 2014-06-25 The Ohio State University Research Foundation Anomalien bei Mikro-RNA-Expressionen in endokrinen und azinösen Pankreastumoren
CN103993082B (zh) 2006-01-05 2017-01-11 俄亥俄州立大学研究基金会 用于肺癌的诊断、预后和治疗的基于微小rna 的方法和组合物
EP2468890B1 (de) 2006-01-05 2014-03-19 The Ohio State University Research Foundation Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von festen Krebsen der Lunge oder Brust
EP2369013A1 (de) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Mikro-RNA-Fingerabdrücke während humaner Megakaryozytopoiese
DK2656841T3 (en) 2006-03-27 2016-12-05 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
RU2449993C2 (ru) 2006-03-29 2012-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилтиогидантоиновые соединения
EP2455492B1 (de) 2006-07-13 2013-11-20 The Ohio State University Research Foundation Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von Krankheiten im Zusammenhang mit dem Dickdarm
ES2374446T3 (es) 2006-09-19 2012-02-16 The Ohio State University Research Foundation Expresión de tcl1 en la leucemia linfocítica crónica (llc) regulada por mir-29 y mir-181.
WO2008054828A2 (en) 2006-11-01 2008-05-08 The Ohio State University Research Foundation Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma
EP2109687B1 (de) 2007-01-31 2014-06-04 The Ohio State University Research Foundation Micro-rna-basierte verfahren zur behandlung von akuter myeloischer leukämie (aml)
WO2008112283A2 (en) * 2007-03-12 2008-09-18 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Microrna profiling of androgen responsiveness for predicting the appropriate prostate cancer treatment
AU2008262252B2 (en) 2007-06-08 2013-09-12 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for determining hepatocellular carcinoma subtype and detecting hepatic cancer stem cells
US8053186B2 (en) 2007-06-15 2011-11-08 The Ohio State University Research Foundation Oncogenic ALL-1 fusion proteins for targeting Drosha-mediated microRNA processing
JP2010535782A (ja) 2007-07-31 2010-11-25 ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン Ｄｎｍｔ３ａ及びｄｎｍｔ３ｂを標的にすることによるメチル化を元に戻す方法
EP2173908B1 (de) 2007-08-03 2016-01-06 The Ohio State University Research Foundation Ultrakonservierte bereiche zur kodierung von ncrnas
CA2696887C (en) 2007-08-22 2016-06-28 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
AU2008316577B2 (en) 2007-10-26 2014-04-10 The Ohio State University Research Foundation Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
CA2966280A1 (en) * 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds
US20110054009A1 (en) * 2008-02-28 2011-03-03 The Ohio State University Research Foundation MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Prostate Related Disorders
JP5745401B2 (ja) 2008-06-11 2015-07-08 アメリカ合衆国 肝細胞癌についての予測マーカーとしてのＭｉＲ−２６ファミリーの使用および療法に対する反応性
AU2010321555B2 (en) 2009-11-23 2015-10-15 The Ohio State University Materials and methods useful for affecting tumor cell growth, migration and invasion
WO2011103202A2 (en) 2010-02-16 2011-08-25 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
WO2012065051A1 (en) 2010-11-12 2012-05-18 Enzon Pharmaceuticals, Inc. Compositions and methods for treating androgen receptor dependent disorders including cancers
ES2606146T3 (es) 2010-11-12 2017-03-22 The Ohio State University Research Foundation Métodos relacionados con microARN-21 y reparación de desapareamiento en cáncer colorrectal
CN103313706A (zh) 2010-11-15 2013-09-18 俄亥俄州立大学研究基金会 控制释放粘膜粘合系统
EP2683387A4 (de) 2011-03-07 2014-09-03 Univ Ohio State Durch mikro-rna-155 (mir-155) induzierte mutatorgenaktivität gegen entzündungen und krebs
WO2013056217A1 (en) 2011-10-14 2013-04-18 The Ohio State University Methods and materials related to ovarian cancer
JP2015501843A (ja) 2011-12-13 2015-01-19 オハイオ・ステイト・イノベーション・ファウンデーション ｍｉＲ−２１およびｍｉＲ−２９ａ、エキソソーム阻害、およびがん転移に関する方法および組成物
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
KR20220025231A (ko) 2012-09-26 2022-03-03 아라곤 파마슈티컬스, 인코포레이티드 비전이성 거세 저항성 전립선암 치료용 항안드로겐
EP2912194B1 (de) * 2012-10-26 2019-05-08 Memorial Sloan-Kettering Cancer Center Androgenrezeptorvarianten und verfahren zur herstellung und verwendung
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
KR102417496B1 (ko) * 2019-11-29 2022-07-06 (주)수파드엘릭사 안드로겐 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
ZA786739B (en) 1977-12-01 1980-07-30 Wellcome Found Hydantoin derivatives and salts thereof,their syntheses,and intermediates,and pharmaceutical formulations
EP0004723A1 (de) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A (fi) 1979-04-24 1980-10-25 Hoffmann La Roche Foerfarande foer framstaellning av imidazolidinderivat
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
EP0748220A4 (de) 1994-01-21 1997-09-10 Sepracor Inc Verfahren und zusammensetzungen zur behandlung von androgen-abhängigen krankheiten unter verwenddung von optisch reinem r-(-)casodex
US5691335A (en) 1994-07-29 1997-11-25 Suntory Limited Imidazolidine derivative and use thereof
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
CA2238812A1 (en) 1995-11-28 1997-06-05 Theodore Sylvester Sulkowski 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) * 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
EP1122242B1 (de) 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl-derivate
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
HUP0402338A3 (en) 2001-10-01 2008-10-28 Bristol Myers Squibb Co Spiro-hydantoin compounds, their use as anti-inflammatory agents, pharmaceutical compositions containing them and intermediates for preparing them
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US20060127902A1 (en) 2002-08-15 2006-06-15 Genzyme Corporation Brain endothelial cell expression patterns
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
AU2003279442A1 (en) 2002-10-04 2004-04-23 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7271188B2 (en) 2003-06-12 2007-09-18 Chugai Seikayu Kabushiki Kaisha Imidazolidine derivatives
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
WO2005059109A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
US7718684B2 (en) 2004-02-24 2010-05-18 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
AU2005222627A1 (en) 2004-03-15 2005-09-29 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives for inhibiting angiogenesis
EP1621539A1 (de) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocyclische-substituirte cyclische Harnstoffderivate, Verfaren zu ihrer Herstellung, und ihre pharmaceutische Verwendung als Kinase Inhibitoren
US7803826B2 (en) 2004-08-03 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Imidazolidine derivatives
CA2579886A1 (en) 2004-09-09 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Novel imidazolidine derivative and use thereof
DK2444085T3 (en) 2005-05-13 2015-04-27 Univ California Diarylhydantoinforbindelser as androgenreceptorantagonister for treating cancer
DK2656841T3 (en) 2006-03-27 2016-12-05 Univ California Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
RU2449993C2 (ru) 2006-03-29 2012-05-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Диарилтиогидантоиновые соединения
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins

Also Published As

Publication number Publication date
JP2007514442A (ja) 2007-06-07
ATE502298T1 (de) 2011-04-15
US8034548B2 (en) 2011-10-11
EP2299266A1 (de) 2011-03-23
WO2005060661A2 (en) 2005-07-07
WO2005060661A3 (en) 2005-08-04
CA2550447A1 (en) 2005-07-07
US20070166717A1 (en) 2007-07-19
EP1709193A2 (de) 2006-10-11
EP1709193B1 (de) 2011-03-16
EP1709193A4 (de) 2007-11-14
NZ548209A (en) 2009-07-31
AU2004305075A1 (en) 2005-07-07

Similar Documents

Publication Publication Date Title
DE602004031881D1 (de) Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A3 (en) Methods and materials for assessing prostate cancer therapies and compounds
CY1120434T1 (el) Πρωτεϊνες προσδεσης il-1
ZA200904353B (en) In vivo screening models for treatment of alzheimer's disease and other Qpct-related disorders
ATE408032T1 (de) Esr1 und gebärmutterhalskrebs
DE602006016567D1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
JP2010500565A5 (de)
GB201315760D0 (en) Methods and compositions of molecular profiling for disease diagnostics
DK1597391T3 (da) Anvendelse af intron-RNA til måling af genekspression
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2005048823A3 (en) Modeling of systemic inflammatory response to infection
ATE514090T1 (de) Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
WO2011133949A3 (en) Genetic risk analysis in reward deficiency syndrome
WO2007112350A3 (en) Method of assessing the metastatic status of a primary tumor
ATE414701T1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
WO2005099449A3 (en) Animal model, cells, and treatment for malignant melanoma
Park et al. Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+ 4 prostate cancers at biopsy: finding a new group eligible for active surveillance
WO2005086938A3 (en) Artificial mutation controls for diagnostic testing
DE60040413D1 (de) Zellen mit defizientem melanocortin-3-rezeptor, transgene mäuse und verfahren zur auswahl von substanzen, die das körpergewicht regulieren können
ATE394676T1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
WO2004004447A3 (en) Agouti-related protein deficient cells, non-human transgenic animals and methods of selecting compounds which regulate energy metabolism
DE10345021A1 (de) Verfahren zur nichtinvasiven Früherkennung von Dickdarmkrebs und/oder Darmkrebsvorläuferzellen
DE60323677D1 (de) Verfahren zur bestimmung des wiederauftretens von prostata krebs
ATE529745T1 (de) Verfahren zur bewertung des hautempfindlichkeitsniveaus durch verwendung von mit plattenepithelkarzinom zusammenhängendem antigen als indikation
WO2006094223A3 (en) Use of prostate specific antigen to predict drug response